##
Read review Dihexa for Endometriosis Brain Fog The November 2025 Lancet O&G/WH 'overlooked symptom' commentary from Edinburgh EXPPECT, the April 2025 Horn FACT-Cog 1,239-patient survey (~80% perceived cognitive impairment), the March 2025 NICE TA1057 Ryeqo approval (first daily pill on NHS), the April 2024 NICE NG73 update, the April 2026 renewed Womens Health Strategy with 117 action points, the 2023 Greaves CNS-wide glial activation mouse model, the BDNF/TrkB central-sensitisation directionality paradox, and the ~1.5 million UK women affected
Common Factors Affecting Peptide Dosing Protocols When a clinician writes a peptide plan, they look at a lot of things: Patient goals and symptoms Medical and injury history Contraindications and current meds ADT: Previous exposure to peptides Method of administration Product concentration Time frame of treatment The monitoring plan Non-clinicians shouldn't make these choices, and don't just copy what other clinics do without review by your medical director
Versus retatrutide (the triple agonist) Retatrutide represents the next frontier
That said, muscle soreness and slow recovery can also be tied to: Not enough calories or protein Low iron or B12 Poor sleep High stress load Thyroid patterns Overtraining Underhydration and electrolyte issues So even if someone is curious about BPC-157, you still want to assess the basics
